Miastenia gravis ocular y factores asociados al desarrollo de una generalización secundaria: descripción de una serie española / Ocular myasthenia gravis and risk factors for developing a secondary generalisation: Description of a Spanish series

Introducción: La miastenia gravis ocular (MGo) es la forma de presentación de la enfermedad más frecuente. Un porcentaje variable de estos pacientes desarrollan una forma generalizada (MGg), siendo los factores de riesgo de conversión y el efecto protector del tratamiento inmunosupresor objeto de controversia en el momento actual. Pacientes y métodos: Diseñamos un estudio monocéntrico retrospectivo, con el objetivo de describir las características demográficas, clínicas y de laboratorio de una cohorte española de MGo, a partir de una serie de MG registrada en el Hospital Universitario de Albacete desde enero del 2008 hasta febrero de 2020. Resultados: Seleccionamos 62 pacientes con MGo de una cohorte de 91 sujetos con MG (68,1%). La mediana de edad al diagnóstico fue de 68 (RIQ 52-75,3), con predominio de MGo de inicio muy tardío (n = 34, 54,8%) y de varones (n = 38, 61,3%). La diplopía binocular fue el síntoma inicial más frecuente (51,7%). La tasa de conversión a MGg fue del 50% (n = 31), con una mediana de tiempo de seis meses (RIQ 2-12,8). Encontramos asociación significativa entre ser mujer (OR: 5,46, IC 95% 1,16-25-74, p = 0,03) y tener AcAchR (OR: 8,86, IC 95% 1,15-68,41, p = 0,04), con el riesgo de desarrollar una MGg. Conclusiones: La tasa de conversión de MGo en nuestra serie es relativamente elevada. La generalización tiene lugar principalmente durante los primeros dos años de evolución y está asociada al sexo femenino y, sobre todo, a la presencia de AcAchR.(AU)

Introduction: Ocular myasthenia gravis (MG) is the most common phenotype of MG at onset. A variable percentage of these patients develop secondary generalisation; the risk factors for conversion and the protective effect of immunosuppressive treatment are currently controversial. Patients and methods: We designed a retrospective single-centre study with the aim of describing the demographic, clinical, and laboratory characteristics of a Spanish cohort of patients with ocular MG from Hospital Universitario de Albacete from January 2008 to February 2020. Results: We selected 62 patients with ocular MG from a cohort of 91 patients with MG (68.1%). Median age at diagnosis was 68 (IQR, 52-75.3), and men accounted for 61.3% of the sample (n = 38). Most patients presented very late-onset ocular MG (n = 34, 54.8%). Binocular diplopia was the most frequent initial symptom (51.7%). The rate of progression to generalised MG was 50% (n = 31), with a median time of 6 months (IQR, 2-12.8). Female sex (OR: 5.46; 95% CI, 1.16-25-74; p = .03) and anti–acetylcholine receptor antibodies (OR: 8.86; 95% CI, 1.15-68.41; p = .04) were significantly associated with the risk of developing generalised MG. Conclusions: The conversion rate observed in our series is relatively high. Generalisation of MG mainly occurs during the first 2 years of progression, and is strongly associated with female sex and especially with the presence of anti–acetylcholine receptor antibodies.(AU)

Descripción de una serie de pacientes con miastenia gravis refractaria / A series of patients with refractory myasthenia gravis

Introducción: Los avances en el tratamiento de la miastenia gravis (MG) han conseguido mejoría en la calidad de vida y el pronóstico de la mayoría de los pacientes. Sin embargo, un 10-20% presenta la denominada MG refractaria sin alcanzar mejoría, con frecuentes recaídas e importante repercusión funcional. Pacientes y métodos: Se seleccionó a pacientes con MG refractaria a partir de una cohorte de pacientes con MG diagnosticados desde enero del 2008 hasta junio del 2019. Se definió MG refractaria como falta de respuesta al tratamiento con prednisona y al menos 2 inmunosupresores o imposibilidad para la retirada del tratamiento sin recaídas en los últimos 12 meses o intolerancia al mismo con graves efectos secundarios. Resultados: Se registraron 84 pacientes con MG, 11 cumplían los criterios de MG refractaria (13%), con una edad media de 47 ± 18 años; un 64% los pacientes con MG refractaria fueron clasificados como miastenia generalizada de comienzo precoz (p < 0,01) con una mayor proporción de mujeres (p < 0,01). La gravedad de la enfermedad al diagnóstico, así como en el momento del análisis de los datos, fue superior en el grupo de MG refractaria con un mayor número de recaídas en el seguimiento. En el modelo de regresión logística se obtuvo una asociación independiente entre MG-R y el número de reagudizaciones graves. Conclusiones: El porcentaje de pacientes con MG refractaria en nuestra serie (13%) es similar al descrito en estudios previos, con frecuencia mujeres con inicio precoz, formas graves de inicio y reiteradas reagudizaciones con ingreso hospitalario en el seguimiento.(AU)

Introduction: Advances in the treatment of myasthenia gravis (MG) have improved quality of life and prognosis for the majority of patients. However, 10%-20% of patients present refractory MG, with frequent relapses and significant functional limitations. Patients and methods: Patients with refractory MG were selected from a cohort of patients diagnosed with MG between January 2008 and June 2019. Refractory MG was defined as lack of response to treatment with prednisone and at least 2 immunosuppressants, inability to withdraw treatment without relapse in the last 12 months, or intolerance to treatment with severe adverse reactions. Results: We identified 84 patients with MG, 11 of whom (13%) met criteria for refractory MG. Mean (standard deviation) age was 47 (18) years; 64% of patients with refractory MG had early-onset generalised myasthenia (as compared to 22% in the group of patients with MG; P<.01), with a higher proportion of women in this group (P<.01). Disease severity at diagnosis and at the time of data analysis was higher among patients with refractory MG, who presented more relapses during follow-up. Logistic regression analysis revealed an independent association between refractory MG and the number of severe relapses. Conclusions: The percentage of patients with refractory MG in our series (13%) is similar to those reported in previous studies; these patients were often women and presented early onset, severe forms of onset, and repeated relapses requiring hospital admission during follow-up.(AU)

A series of patients with refractory myasthenia gravis.

INTRODUCTION: Advances in the treatment of myasthenia gravis (MG) have improved quality of life and prognosis for the majority of patients. However, 10%-20% of patients present refractory MG, with frequent relapses and significant functional limitations. PATIENTS AND METHODS: Patients with refractory MG were selected from a cohort of patients diagnosed with MG between January 2008 and June 2019. Refractory MG was defined as lack of response to treatment with prednisone and at least 2 immunosuppressants, inability to withdraw treatment without relapse in the last 12 months, or intolerance to treatment with severe adverse reactions. RESULTS: We identified 84 patients with MG, 11 of whom (13%) met criteria for refractory MG. Mean (standard deviation) age was 47 (18) years; 64% of patients with refractory MG had early-onset generalised myasthenia (as compared to 22% in the group of patients with MG; P < .01), with a higher proportion of women in this group (P < .01). Disease severity at diagnosis and at the time of data analysis was higher among patients with refractory MG, who presented more relapses during follow-up. Logistic regression analysis revealed an independent association between refractory MG and the number of severe relapses. CONCLUSIONS: The percentage of patients with refractory MG in our series (13%) is similar to those reported in previous studies; these patients were often women and presented early onset, severe forms of onset, and repeated relapses requiring hospital admission during follow-up.

Ocular myasthenia gravis and risk factors for developing a secondary generalisation: description of a Spanish series.

INTRODUCTION: Ocular myasthenia gravis (MG) is the most common phenotype of MG at onset. A variable percentage of these patients develop secondary generalisation; the risk factors for conversion and the protective effect of immunosuppressive treatment are currently controversial. PATIENTS AND METHODS: We designed a retrospective single-centre study with the aim of describing the demographic, clinical, and laboratory characteristics of a Spanish cohort of patients with ocular MG from Hospital Universitario de Albacete from January 2008 to February 2020. RESULTS: We selected 62 patients with ocular MG from a cohort of 91 patients with MG (68.1%). Median age at diagnosis was 68 (IQR, 52-75.3), and men accounted for 61.3% of the sample (n = 38). Most patients presented very late-onset ocular MG (n = 34, 54.8%). Binocular diplopia was the most frequent initial symptom (51.7%). The rate of progression to generalised MG was 50% (n = 31), with a median time of 6 months (IQR, 2-12.8). Female sex (OR: 5.46; 95% CI, 1.16-25-74; P= .03) and anti-acetylcholine receptor antibodies (OR: 8.86; 95% CI, 1.15-68.41; P = .04) were significantly associated with the risk of developing generalised MG. CONCLUSIONS: The conversion rate observed in our series is relatively high. Generalisation of MG mainly occurs during the first 2 years of progression, and is strongly associated with female sex and especially with the presence of anti-acetylcholine receptor antibodies.

[Myasthenia gravis induced by atezolizumab]. / Miastenia gravis inducida por atezolizumab.

TITLE: Miastenia gravis inducida por atezolizumab.

A series of patients with refractory myasthenia gravis. / Descripción de una serie de pacientes con miastenia gravis refractaria.

INTRODUCTION: Advances in the treatment of myasthenia gravis (MG) have improved quality of life and prognosis for the majority of patients. However, 10%-20% of patients present refractory MG, with frequent relapses and significant functional limitations. PATIENTS AND METHODS: Patients with refractory MG were selected from a cohort of patients diagnosed with MG between January 2008 and June 2019. Refractory MG was defined as lack of response to treatment with prednisone and at least 2 immunosuppressants, inability to withdraw treatment without relapse in the last 12 months, or intolerance to treatment with severe adverse reactions. RESULTS: We identified 84 patients with MG, 11 of whom (13%) met criteria for refractory MG. Mean (standard deviation) age was 47 (18) years; 64% of patients with refractory MG had early-onset generalised myasthenia (as compared to 22% in the group of patients with MG; P<.01), with a higher proportion of women in this group (P<.01). Disease severity at diagnosis and at the time of data analysis was higher among patients with refractory MG, who presented more relapses during follow-up. Logistic regression analysis revealed an independent association between refractory MG and the number of severe relapses. CONCLUSIONS: The percentage of patients with refractory MG in our series (13%) is similar to those reported in previous studies; these patients were often women and presented early onset, severe forms of onset, and repeated relapses requiring hospital admission during follow-up.

Ocular myasthenia gravis and risk factors for developing a secondary generalisation: Description of a Spanish series. / Miastenia gravis ocular y factores asociados al desarrollo de una generalización secundaria: descripción de una serie española.

INTRODUCTION: Ocular myasthenia gravis (MG) is the most common phenotype of MG at onset. A variable percentage of these patients develop secondary generalisation; the risk factors for conversion and the protective effect of immunosuppressive treatment are currently controversial. PATIENTS AND METHODS: We designed a retrospective single-centre study with the aim of describing the demographic, clinical, and laboratory characteristics of a Spanish cohort of patients with ocular MG from Hospital Universitario de Albacete from January 2008 to February 2020. RESULTS: We selected 62 patients with ocular MG from a cohort of 91 patients with MG (68.1%). Median age at diagnosis was 68 (IQR, 52-75.3), and men accounted for 61.3% of the sample (n = 38). Most patients presented very late-onset ocular MG (n = 34, 54.8%). Binocular diplopia was the most frequent initial symptom (51.7%). The rate of progression to generalised MG was 50% (n = 31), with a median time of 6 months (IQR, 2-12.8). Female sex (OR: 5.46; 95% CI, 1.16-25-74; p = .03) and anti-acetylcholine receptor antibodies (OR: 8.86; 95% CI, 1.15-68.41; p = .04) were significantly associated with the risk of developing generalised MG. CONCLUSIONS: The conversion rate observed in our series is relatively high. Generalisation of MG mainly occurs during the first 2 years of progression, and is strongly associated with female sex and especially with the presence of anti-acetylcholine receptor antibodies.

HiperCKemia paucisintomática secundaria a mutación en el gen ANO5 / Paucisymptomatic hyperCKemia due to a mutation in the ANO5 gene

No disponible

Multiple sclerosis following SARS-CoV-2 infection.

SARS-CoV-2 infection can produce neurological features. The most common are headache, anosmia and dysgeusia but patients may also develop other central nervous system (CNS) injuries. We present a patient affected by Covid-19 who initially consulted for decreased visual acuity. The MRI showed inflammation in the right optic nerve and demyelinating lesions in the CNS. We speculate that an immune mechanism induced by SARS-CoV-2, which can activate lymphocytes and an inflammatory response, plays a role in the clinical onset of the disease. This pathogen may be associated with either the triggering or the exacerbation of inflammatory/demyelinating disease.

¿Se ha producido un cambio en la etiología del ictus isquémico en las últimas décadas? Análisis y comparación de una base de datos de ictus actual frente a las históricas / Has the aetiology of ischaemic stroke changed in the past decades? Analysis and comparison of data from current and historical stroke databases

OBJETIVOS: Comprobar si han existido variaciones en la etiología del ictus isquémico en los últimos años e investigar las posibles causas que lo justifiquen. PACIENTES Y MÉTODOS: Análisis de los antecedentes epidemiológicos y factores de riesgo vascular de los pacientes diagnosticados de ictus isquémico en el Complejo Hospitalario Universitario de Albacete (CHUA) entre 2009 y 2014. La clasificación etiológica del ictus isquémico se realizó según los criterios TOAST. Se compararon los resultados con los de la clásica Stroke Data Bank (SDB) y se contrastaron ambas series con otros registros hospitalarios publicados en el periodo que las separa. RESULTADOS: Se analiza a 1.664 pacientes, 58% varones, mediana de edad 74 años. Según la clasificación etiológica los resultados obtenidos son (CHUA/SDB): aterotrombóticos (12%/9%), lacunares (13%/25%), cardioembólicos (32%/19%), causa infrecuente (3%/4%) e indeterminados (40%/44%). El 63% de los pacientes del CHUA era mayor de 70 años, en la SDB solo el 42% superaba esa edad. En ambos registros el subtipo cardioembólico era más prevalente en mayores de 70 años. La HTA no tratada era más frecuente en la SDB (SDB = 31% vs. CHUA = 10%). El análisis de otras bases de datos muestra una tendencia progresiva a escala mundial al aumento en la prevalencia del ictus cardioembólico. CONCLUSIONES: Nuestro estudio muestra tanto en nuestro centro como a escala mundial una disminución del porcentaje de ictus lacunares y un aumento del de cardioembólicos respecto a la SDB. Estas diferencias pudieran justificarse por el envejecimiento de los pacientes, el mejor control de la HTA actualmente y mayor capacidad para detectar arritmias cardioembólicas en las Unidades de Ictus

OBJECTIVES: We aimed to determine whether the aetiology of ischaemic stroke has changed in recent years and, if so, to ascertain the possible reasons for these changes. PATIENTS AND METHODS: We analysed the epidemiological history and vascular risk factors of all patients diagnosed with ischaemic stroke at Complejo Hospitalario Universitario de Albacete (CHUA) from 2009 to 2014. Ischaemic stroke subtypes were established using the TOAST criteria. Our results were compared to data from the classic Stroke Data Bank (SDB); in addition, both series were compared to those of other hospital databases covering the period between the two. RESULTS: We analysed 1664 patients (58% were men) with a mean age of 74 years. Stroke aetiology in both series (CHUA, SDB) was as follows: atherosclerosis (12%, 9%), small-vessel occlusion (13%, 25%), cardioembolism (32%, 19%), stroke of other determined aetiology (3%, 4%), and stroke of undetermined aetiology (40%, 44%). Sixty-three percent of the patients from the CHUA and 42% of the patients from the SDB were older than 70 years. Cardioembolic strokes were more prevalent in patients older than 70 years in both series. Untreated hypertension was more frequent in the SDB (SDB = 31% vs CHUA = 10%). The analysis of other databases shows that the prevalence of cardioembolic stroke is increasing worldwide. CONCLUSIONS: Our data show that the prevalence of lacunar strokes is decreasing worldwide whereas cardioembolic strokes are increasingly more frequent in both our hospital and other series compared to the SDB. These differences may be explained by population ageing and the improvements in management of hypertension and detection of cardioembolic arrhythmias in stroke units

Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia.

BACKGROUND: Antiepileptic drugs are the first-line treatment for trigeminal neuralgia (TN). Carbamazepine and oxcarbazepine are the most studied with well-known efficacy. Eslicarbazepine acetate is a third-generation antiepileptic drug that has not previously been evaluated for the treatment of TN. We aim to assess the efficacy, tolerability and safety of eslicarbazepine for TN. DESIGN AND METHODS: Retrospective, open-label, multicentric, intention-to-treat study. We included patients older than 18 years who met the ICHD-3 beta diagnostic criteria for TN. We evaluated the variation of intensity and frequency of pain paroxysms before and after treatment with eslicarbazepine. Secondary objectives assessed were tolerability and safety of eslicarbazepine. RESULTS: Eighteen patients were included, 15 women, mean age 65.2 years old, mean follow-up 21.1 months. The mean number of drugs tested before eslicarbazepine was 2; 10 patients used eslicarbazepine as monotherapy. After the treatment with ESL, the median of pain intensity improved from 9.5 to 2.5 (p < 0.001) and the median of pain paroxysms frequency improved from 70 episodes per week to 0.37 (p < 0.001). Responder rate was 88.9%; 44.4% became asymptomatic after treatment. Sixty-one per cent of patients presented some adverse event; four patients discontinued eslicarbazepine for this reason. Despite this, 16 patients (88.9%) noticed a good subjective tolerance to eslicarbazepine. The retention rate at 6 months was 77.8% and at 12 months 61.1%. CONCLUSIONS: Our study supports the hypothesis that eslicarbazepine acetate is an effective, safe and well-tolerated treatment for the treatment of TN. Further studies are warranted to corroborate these results. SIGNIFICANCE: Eslicarbazepine acetate has shown to be an effective, safe and well-tolerated drug for TN. This is the first study that evaluated the efficacy of this drug on TN in humans.

Has the aetiology of ischaemic stroke changed in the past decades? Analysis and comparison of data from current and historical stroke databases. / ¿Se ha producido un cambio en la etiología del ictus isquémico en las últimas décadas? Análisis y comparación de una base de datos de ictus actual frente a las históricas.

OBJECTIVES: We aimed to determine whether the aetiology of ischaemic stroke has changed in recent years and, if so, to ascertain the possible reasons for these changes. PATIENTS AND METHODS: We analysed the epidemiological history and vascular risk factors of all patients diagnosed with ischaemic stroke at Complejo Hospitalario Universitario de Albacete (CHUA) from 2009 to 2014. Ischaemic stroke subtypes were established using the TOAST criteria. Our results were compared to data from the classic Stroke Data Bank (SDB); in addition, both series were compared to those of other hospital databases covering the period between the two. RESULTS: We analysed 1664 patients (58% were men) with a mean age of 74 years. Stroke aetiology in both series (CHUA, SDB) was as follows: atherosclerosis (12%, 9%), small-vessel occlusion (13%, 25%), cardioembolism (32%, 19%), stroke of other determined aetiology (3%, 4%), and stroke of undetermined aetiology (40%, 44%). Sixty-three percent of the patients from the CHUA and 42% of the patients from the SDB were older than 70 years. Cardioembolic strokes were more prevalent in patients older than 70 years in both series. Untreated hypertension was more frequent in the SDB (SDB = 31% vs CHUA = 10%). The analysis of other databases shows that the prevalence of cardioembolic stroke is increasing worldwide. CONCLUSIONS: Our data show that the prevalence of lacunar strokes is decreasing worldwide whereas cardioembolic strokes are increasingly more frequent in both our hospital and other series compared to the SDB. These differences may be explained by population ageing and the improvements in management of hypertension and detection of cardioembolic arrhythmias in stroke units.

Estimulación cerebral profunda en la enfermedad de Parkinson / Deep brain stimulation in Parkinson's disease

Introducción. Desde su aparición en la década de los noventa, la estimulación cerebral profunda se ha impuesto como una alternativa terapéutica segura y eficaz en la enfermedad de Parkinson, estando indicada cuando aparecen complicaciones motoras incontrolables con el tratamiento farmacológico. Objetivo. Realizar una revisión actualizada de la literatura médica sobre los aspectos más importantes de esta cirugía funcional. Desarrollo. Aunque su mecanismo de acción a día de hoy continúa siendo desconocido, se ha postulado que ejerce una acción inhibitoria sobre la actividad de los núcleos subtalámico y globo pálido interno, que se encuentra exaltada en enfermos parkinsonianos. La técnica quirúrgica de elección es la estimulación del núcleo subtalámico. Ha demostrado tener unos resultados favorables tanto desde el punto de vista motor, con una mejoría significativa de los síntomas cardinales de la enfermedad, como en la calidad de vida de estos pacientes. El éxito de la cirugía depende de tres pasos fundamentales: 1) La adecuada selección del candidato quirúrgico, teniendo en cuenta las recomendaciones de los principales grupos de estudio sobre factores pronóstico como son la edad, el tiempo de evolución y la presencia de síntomas resistentes a la levodopa. 2) La correcta posición del electrodo en la diana quirúrgica. 3) La programación del sistema de estimulación. Conclusión. La estimulación cerebral profunda del núcleo subtalámico es una opción terapéutica claramente establecida en la enfermedad de Parkinson avanzada, cuyo desarrollo en los últimos años, ha favorecido la obtención de unos resultados clínicos favorables cuando el tratamiento farmacológico fracasa (AU)

Introduction. Since its appearance in the nineties, deep brain stimulation has proved itself to be a safe, effective therapeutic alternative in Parkinson's disease, and is indicated when there are motor complications that pharmacological treatment fails to control. Aims. The purpose of this work is to conduct an updated review of the medical literature on the most important aspects of this functional surgery. Development. Although today its mechanism of action remains unknown, it has been suggested that it exerts an inhibitory action on the activity of the subthalamic nuclei and internal globus pallidus, which is found to be overexcited in patients with parkinsonism. The preferred surgical technique is subthalamic nucleus stimulation. This procedure has proved to yield favourable results both from the motor point of view, with a significant improvement in the cardinal symptoms of the disease, and as regards these patients’ quality of life. The success of the surgical procedure depends on three fundamental steps: 1) Selection of a suitable candidate for surgery, taking into account the recommendations of the main study groups on prognostic factors, such as age, time to progression and the presence of symptoms that are resistant to levodopa; 2) The correct position of the electrode on the surgical target; 3) The programming of the stimulation system. Conclusions. Deep brain stimulation of the subthalamic nucleus is a clearly established therapeutic option in advanced Parkinson's disease. Recent developments allow favourable clinical outcomes to be obtained when pharmacological treatment fails (AU)

Miscelánea: parkinsonismo en otras enfermedades degenerativas / Miscellany: Parkinsonism in other degenerative diseases

Introducción. El parkinsonismo en otras enfermedades neurodegenerativas es un tema amplio y variado. Describiremos las características diferenciadoras de algunas entidades bien definidas (enfermedad de Huntington, enfermedad de Wilson), así como de otras más raras. Desarrollo. Existen gran cantidad de trastornos neurodegenerativos que cursan con parkinsonismo en algún momento de su evolución. Es necesario reconocer marcadores clínicos diferenciadores (edad de inicio, corea, hepatopatía, parálisis supranuclear de la mirada, respuesta a levodopa...), así como patrones de herencia y de neuroimagen que nos permitan reconocer cuadros clínicos definidos. Conclusiones. Todo cuadro de parkinsonismo debe estudiarse cuidadosamente. Debemos identificar aquellos cuadros con especial importancia por su frecuencia (enfermedad de Huntington) o por ser potencialmente curables (enfermedad de Wilson), en especial en todos los pacientes con un inicio juvenil. Otras entidades infrecuentes (hemiatrofia-hemiparkinson, síndrome pálido-piramidal, enfermedades por depósito, neuroacantocitosis, etc), también deben ser consideradas en el diagnóstico diferencial (AU)

Introduction. Parkinsonism in other neurodegenerative diseases is a broad and varied topic. We report the differentiating features of some well-defined conditions (Huntington's disease, Wilson's disease), as well as some other rarer ones. Development. There are many neurodegenerative disorders that are accompanied by parkinsonism at some point in their development. It is necessary to recognise differentiating clinical markers (age at onset, chorea, liver disease, supranuclear gaze palsy, response to levodopa, and so on) as well as inheritance and neuroimaging patterns that enable us to recognise defined clinical pictures. Conclusions. very clinical picture suggestive of parkinsonism must be studied carefully. We must identify those clinical patterns that are especially important due to their frequency (Huntington's disease) or because they are potentially curable (Wilson's disease), particularly in all patients with onset prior to adulthood. Other infrequent conditions (hemiatrophyhemiparkinsonism, pallidal-pyramidal syndrome, diseases due to deposits, neuroacanthocytosis, etc.) should also be taken into account in the differential diagnosis (AU)

[Non-motor disorders in Parkinson's disease: introduction and general features]. / Trastornos no motores de la enfermedad de Parkinson: introducción y generalidades.

INTRODUCTION: Two hundred years ago James Parkinson accurately described the disease that bears his name today, focusing not only on motor aspects but also on non-motor symptoms suffered by these patients. DEVELOPMENT: Non-motor symptoms are prevalent and decrease the quality of life of the patients with Parkinson's disease. In recent years, some non-motor scales have been developed to avoid the problem of underdiagnosis. Moreover, some of them have been proposed as clinical predictors for Parkinson's disease and it is has been suggested that individuals with any of these non-motor symptoms and without motor manifestations of the disease could be the aim for neuroprotective therapies when they become available. CONCLUSIONS: Non-motor symptoms are prevalent and have a great impact in the quality of life of patients. Therefore, it is important to detect and treat them. Their role as predictors of the disease is unclear yet.

[Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers]. / Eficacia de brimonidina 0,2% y dorzolamida 2% como tratamiento adyuvante a un beta-bloqueante.

PURPOSE: To evaluate the clinical efficiency and tolerability of brimonidine and dorzolamide twice daily as an adjunctive therapy for glaucoma patients with an inadequate response to beta-blockers therapy. METHODS: This multicenter prospective analysis included 92 patients (180 eyes) with primary open-angle glaucoma or ocular hypertension on therapy beta-blockers and with intraocular pressure (IOP) greater than or equal to 18mmHg. The patients were randomly treated either with brimonidine 0.2% or dorzolamide 2% added for three months. Efficiency was determined by the reduction in 15% IOP from baseline at the first and the third month. RESULTS: Mean pre-treatment IOP was 22.37 DE 2.8 mmHg in the brimonidine group and 22.38 DE 2.6 mmHg in the dorzolamide group; mean post-treatment IOP decrease was 4.39 mmHg in the brimonidine group and 3.29 mmHg in the dorzolamide group. Clinical control at the first month was achieved in 78.3% and 71% of cases respectively (p=0.05). No statistical differences existed between groups for systemic adverse events. Four patients on brimonidine discontinued treatment due to local side effects. In the dorzolamide group, two patients left the treatment referring itching and three others left due to ocular allergy. CONCLUSIONS: This study found similar efficiency and safety when treating with brimonidine or dorzolamide as an adjunctive therapy for patients with hypertension or primary open-angle glaucoma.

Eficacia de brimonidina 0,2 por ciento y dorzolamida 2 por ciento como tratamiento adyuvante a un beta-bloqueante / Efficiency of brimonidine 0.2 por ciento and dorzolamide 2 por ciento as adjunctive therapy to beta-blockers

Objetivo: Comparar la eficacia y tolerabilidad de brimonidina y dorzolamida dos veces al día cuando se utilizan como terapia coadyuvante con un betabloqueante en pacientes con glaucoma inadecuadamente controlados.Material y métodos: Realizamos un estudio prospectivo, multicéntrico, incluyendo 92 pacientes (180 ojos) diagnosticados de glaucoma o hipertensión ocular, tratados con un beta-bloqueante tópico y cuya presión intraocular (PIO) fuera igual o mayor de 18 mmHg. Se trataron de forma aleatoria con brimonidina 0,2 por ciento o dorzolamida 2 por ciento durante tres meses. Evaluamos la eficacia considerando el descenso medio de la PIO basal de un 15 por ciento al mes y a los 3 meses.Resultados: La PIO basal fue de 22,37 DE 2,82 mmHg en los que trataríamos con brimonidina y de 22,38 DE 2,27 en los del grupo de la dorzolamida; el descenso medio de la PIO basal al mes en el grupo de la brimonidina fue 4,39 mmHg y de 3,29 mmHg en el de la dorzolamida. A los tres meses no encontramos diferencias significativas. La respuesta clínica al mes se alcanzó en el 78,3 por ciento de los ojos a los que se había añadido brimonidina y en el 71 por ciento de los que se añadió dorzolamida (p=0,05). Los efectos adversos fueron poco frecuentes en ambos grupos, sin encontrar diferencias significativas. Cuatro pacientes del grupo de la brimonidina abandonaron el tratamiento por queratoconjuntivitis alérgica. En el grupo de la dorzolamida dos pacientes se retiraron del estudio por intolerancia local y tres pacientes por alergia ocular.Conclusiones: La brimonidina y la dorzolamida reducen eficazmente la PIO como tratamiento coadyuvante al beta-bloqueante cuando éste es insuficiente para conseguir una PIO adecuada en pacientes con hipertensión ocular o glaucoma primario de ángulo abierto. (AU)

[Indocyanine green angiography in chorioretinal inflammatory diseases]. / Valoración de enfermedades inflamatorias coriorretinianas con angiografía verde indocianina.

PURPOSE: To determine the role of indocyanine green angiography (ICG) in handling chorioretinal inflammatory disorders. METHOD: We present several posterior uveitis whose diagnosis and therapeutic approach was facilitated with ICG. RESULTS: ICG is useful in the differential diagnosis of <>. In serpiginous choroiditis, the edges and the progression of the inflammatory areas are clearly delineated. In infectious uveitis such as toxoplasmosis, ICG determines the presence or absence of active lesions. There are granulomatous diseases such as sarcoidosis where some areas of choroidal inflammation that cannot be detected with other methods are shown by ICG. Moreover, ICG can detect areas of subretinal neovascularization in some choroidal pathologies such as polypoidal choroidal vasculopathy. CONCLUSIONS: ICG appears to be a useful and complementary tool in the clinical interpretation of posterior uveitis.